Konica Minolta Accelerates Expansion of Precision Medicine Business Through Acquisition of US-based Pharmaceutical Research Company, Invicro
Through molecular digital imaging technology, acquisition offers new value for drug discovery and development focused on the fields of immuno-oncology and neurodegenerative disease
TOKYO & BOSTON–(BUSINESS WIRE)–Konica Minolta, Inc. (“Konica Minolta”) (TOKYO: 4902; ISIN: JP3300600008) and Boston-based Invicro LLC (“Invicro”) today announced that they have concluded an agreement whereby Konica Minolta will acquire Invicro, a leading provider of imaging services and software for research and drug development.